Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Radiosensitization in bladder cancer

Wassim Kassouf • 15 Feb 2020
GU Cancers 2020
Bladder Cancer Genitourinary Cancer Antibodies Checkpoint Inhibitors Durvalumab

Wassim Kassouf, FRCS, MD, McGill University Health Centre, Montreal, Canada, discusses the combination of radiation with immune checkpoint inhibition in bladder cancer. Prof. Kassouf goes on to discuss BL13 (NCT03768570), an open-label randomized trial investigating trimodality therapy with or without durvalumab to treat patients with muscle-invasive bladder cancer. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Wassim Kassouf

1:19
Treating BCG-unresponsive bladder cancer
Wassim Kassouf • 15 Feb 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals